High-Dose Mizoribine Treatment for Adolescents with Systemic Lupus Erythematosus

    April 2006 in “ Pediatrics International ”
    Kandai Nozu, Kazumoto Iijima, Ichiro Kamioka, Teruo Fujita, Kunihiko Yoshiya, Ryojiro Tanaka, Koichi Nakanishi, Norishige Yoshikawa, Masafumi Matsuo
    TLDR High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.
    The study investigated the use of high-dose mizoribine (MZR) at 300 mg/day in five adolescents with systemic lupus erythematosus (SLE), which was double the conventional adult dose. The treatment aimed to achieve remission while minimizing the adverse effects associated with prolonged immunosuppressant use. The results indicated that high-dose MZR was effective in controlling symptoms and reducing steroid dependency, with satisfactory efficacy observed in all patients. Side effects included hyperuricemia in two patients, which was managed by dose adjustment or resolved spontaneously, and temporary hair loss in two patients, which subsided after a few months. The study concluded that high-dose MZR could be administered effectively and safely, with necessary monitoring of serum uric acid levels, suggesting its potential application for steroid-dependent pediatric SLE patients.
    Discuss this study in the Community →